Posted by Michael Wonder on 12 Dec 2017
FDA approves first drug for eosinophilic granulomatosis with polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
12 December 2017 - The U.S. FDA today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood vessels of the body.
This new indication provides the first FDA-approved therapy specifically to treat EGPA.
The FDA granted this application priority review and orphan drug designations.
